Plastic surgeon and author Dr. Benoit Hendrickx analyzes current biotech and clinical data to argue that biological constraints cap human lifespan near 120 years, advocating research on healthspan enhancement via senolytics, metabolic regulators, and lifestyle optimization.
Key points
- Dr. Benoit Hendrickx reviews current biotech and clinical research on senolytics targeting cellular senescence.
- He estimates human maximum lifespan near 120 years based on genetic and physiological constraints.
- Telomere extension experiments in lab models show lifespan gains but heighten cancer risk.
- GLP-1 analogs like Ozempic may reduce obesity-related mortality and improve metabolic health.
- Lifestyle measures—calorie control, exercise, sensory health, social engagement—are central to healthspan.
- Metformin and other senolytic compounds are in early clinical trials with inconclusive results.
Why it matters: By dispelling the myth of millennium-long lifespans, this analysis refocuses geroscience on achievable healthspan improvements rather than unattainable immortality. Emphasizing therapies like senolytics and metabolic regulators sets a pragmatic roadmap for future anti-aging research.
Q&A
- What are senolytics?
- How does telomere length influence lifespan?
- Why prioritize healthspan over lifespan?
- How do GLP-1 analogs support longevity?
